Last $27.98 USD
Change Today -0.02 / -0.07%
Volume 266.4K
CYNO On Other Exchanges
Symbol
Exchange
CYNO is not on other exchanges.
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

cynosure inc-a (CYNO) Snapshot

Open
$28.00
Previous Close
$28.00
Day High
$28.18
Day Low
$27.83
52 Week High
02/28/14 - $31.48
52 Week Low
07/28/14 - $18.63
Market Cap
605.7M
Average Volume 10 Days
220.2K
EPS TTM
$0.66
Shares Outstanding
21.6M
EX-Date
--
P/E TM
42.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for CYNOSURE INC-A (CYNO)

cynosure inc-a (CYNO) Related Businessweek News

View More BusinessWeek News

cynosure inc-a (CYNO) Details

Cynosure, Inc. develops, manufactures, and markets aesthetic treatment systems primarily to the dermatology, plastic surgery, and general medical markets. Its aesthetic treatment systems incorporate a range of laser and other light-based energy sources, including Alexandrite, pulse dye, Nd:YAG, Er:YAG, Erbium:glass, CO2, and diode lasers, as well as intense pulsed light devices. The company’s aesthetic treatment systems comprise Elite product line for hair removal, treatment of facial, and leg veins and pigmentations; Smartlipo product line for LaserBodySculpting for the removal of unwanted fat; Cellulaze product line for the treatment of cellulite; SmoothShapes XV product line for the temporary reduction in the appearance of cellulite; Affirm/SmartSkin product line for anti-aging applications, including treatments for wrinkles, skin texture, skin discoloration, and skin tightening; Cynergy product line for the treatment of vascular lesions; and Accolade, MedLite C6, and RevLite product lines for the removal of benign pigmented lesions, as well as multi-colored tattoos, as well as PicoSure product line for the treatment of tattoos and benign pigmented lesions. It also distributes the PinPointe FootLaser, a light-based device for the treatment of onychomycosis. The company sells its products through a direct sales force in North America, France, Spain, the United Kingdom, Germany, Korea, China, Japan, Australia, and Mexico, as well as through independent distributors in approximately 120 other countries. Cynosure, Inc. was founded in 1991 and is headquartered in Westford, Massachusetts.

576 Employees
Last Reported Date: 03/17/14
Founded in 1991

cynosure inc-a (CYNO) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $2.2M
President, Chief Operating Officer, Chief Fin...
Total Annual Compensation: $1.4M
Executive Vice President of Worldwide Sales
Total Annual Compensation: $1.0M
Compensation as of Fiscal Year 2013.

cynosure inc-a (CYNO) Key Developments

Cynosure, Inc. Discusses Favorable Clinical Data from Trial of MonaLisa Touch(TM) Laser Treatment

Cynosure, Inc. announced that clinical data will be presented at a national meeting of gynecologists and ObGyns that will show a statistically significant improvement in the vaginal health of women treated with the MonaLisa Touch(TM) fractional carbon dioxide (CO(2)) laser. Cynosure has a agreement to market the laser in North America for the treatment of gynecology indications including vaginal atrophy, a condition affecting primarily postmenopausal women, breast cancer survivors and women who have undergone hysterectomies. At the 2014 Pelvic Anatomy and Gynecologic Surgery Symposium (PAGS) in Las Vegas, a symposium titled, A New and Novel Therapy for Vulvovaginal Atrophy: Results of the First U.S. Trial will describe preliminary findings from a trial evaluating the laser treatment on postmenopausal women and breast cancer survivors experiencing vaginal health issues. The data will be presented by Dr. Mickey Karram, Director of Fellowship Program on Female Pelvic Medicine & Reconstructive Surgery, The Christ Hospital, Cincinnati, OH and Dr. Eric Sokol, Associate Professor of Obstetrics and Gynecology at the Stanford University Medical Center. The multicenter trial assessed the use of CO(2) fractional laser therapy on 30 women with vaginal health issues due to menopause. All of the patients were treated with MonaLisa Touch, which delivers CO(2) laser energy to the vaginal wall to promote vaginal mucosal revitalization and a return to premenopausal vaginal health. This minimally invasive, painless procedure was performed in an office setting and required no anesthesia. It was performed in three treatments, each taking less than five minutes, six weeks apart. Issues of vaginal health are commonly seen in postmenopausal women, breast cancer survivors and women who have had a hysterectomy. The MonaLisa Touch treatment is particularly well suited for patients who cannot, or elect not to, receive estrogen therapy. The system is designed to stimulate and promote the regeneration of collagen fibers and the restoration of hydration and elasticity within the vaginal mucosa. The laser is able to release energy through a special pulse, and the laser energy heat penetrates to a depth that stimulates the synthesis of new collagen which results in the thickening of the vaginal skin, increasing moisture and better lubrication which restores the vagina to a state similar to before menopause.

Cynosure, Inc. Signs Exclusive Agreement to Market MonaLisa Touch(TM) in North America for Gynecology Indications

Cynosure, Inc. announced that it has signed an exclusive agreement with El.En. S.p.A. to market and distribute in North America the MonaLisa Touch(TM), a carbon dioxide (CO(2)) laser for the treatment of vaginal atrophy, a condition that affects primarily postmenopausal women, breast cancer survivors and women who have undergone hysterectomies. Cynosure plans to introduce the MonaLisa Touch at the 2014 Pelvic Anatomy and Gynecologic Surgery Symposium (PAGS), which takes place next month in Las Vegas. The Company expects to begin selling the product in the U.S. in the first quarter of 2015 through a specialty surgical sales force. The MonaLisa Touch delivers short CO(2) ablative laser pulses to the vaginal wall, decreasing vaginal atrophy symptoms such as vaginal dryness, soreness and itching as well as painful urination and intercourse. The device received marketing clearance from the U.S. Food and Drug Administration in September 2014. Results of a recently published study of postmenopausal women who received three applications of the MonaLisa Touch laser over a 12-week period concluded that the device induced a significant improvement of vaginal atrophy symptoms. Recent clinical work also has been conducted to investigate the effects of the laser on sexual function and overall satisfaction with sexual life in postmenopausal women with vaginal atrophy. Treatment with the MonaLisa Touch is designed to reverse the deterioration of the vaginal walls associated with the loss of estrogen due to aging, hormonal treatments for breast cancer, and other conditions. The system is designed to stimulate and promote the regeneration of collagen fibers and the restoration of hydration and elasticity within the vaginal mucosa.

Cynosure, Inc. Presents at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum, Nov-20-2014 11:00 AM

Cynosure, Inc. Presents at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum, Nov-20-2014 11:00 AM. Venue: The Westin Grand Central, New York, New York, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYNO:US $27.98 USD -0.02

CYNO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cutera Inc $9.90 USD -0.08
Lutronic Corp 21,300 KRW +200.00
PhotoMedex Inc $1.42 USD -0.04
Syneron Medical Ltd $9.60 USD +0.07
Zeltiq Aesthetics Inc $28.48 USD -0.25
View Industry Companies
 

Industry Analysis

CYNO

Industry Average

Valuation CYNO Industry Range
Price/Earnings 39.7x
Price/Sales 2.2x
Price/Book 1.8x
Price/Cash Flow 31.8x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYNOSURE INC-A, please visit www.cynosure.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.